论文部分内容阅读
目的探讨拉米夫定联合干扰素在慢性乙型肝炎中的应用。方法随机分为联合组(拉米夫定联合干扰素)40例,其中男25例,女15例,ALT均值(118±38)U/L;拉米夫定组40例,男26例,女14例。结果HBV DNA阴转率联合组为100%(40/40),拉米夫定组为100%(40/40);HBeAg血清转换率联合组为70%(34/40),拉米夫定组为35%(12/40);HBeAg阴转率联合组为72%(32/40),拉米夫定组为40%(15/40);ALT复常率联合组为100%(40/40),拉米夫定组为98%(39/40)。结论拉米夫定联合干扰素的治疗能迅速控制病毒血症,改善肝功能,稳定病情,使血清HBeAg转换率提高,可减少停药后的复发率,加快HBV DNA的阴转,疗效较为满意;两药联合应用分别作用于不同的靶位和机制,相互促进能提高疗效,降低拉米夫定的耐药性的发生。
Objective To investigate the application of lamivudine combined with interferon in chronic hepatitis B patients. Methods Forty patients (25 males and 15 females) with ALT (118 ± 38) U / L were randomly divided into combined group (lamivudine combined with interferon), 40 patients with lamivudine, 26 males, Female 14 cases. Results The rate of HBV DNA negative conversion was 100% (40/40) in the combination group and 100% (40/40) in the lamivudine group. The HBeAg seroconversion rate in the combination group was 70% (34/40) (12/40), HBeAg negative rate in combination group was 72% (32/40), lamivudine group was 40% (15/40), ALT rate was 100% (40 / 40), lamivudine group was 98% (39/40). Conclusion The combination of lamivudine and interferon can rapidly control viraemia, improve liver function, stabilize the condition, increase the serum HBeAg conversion rate, reduce the relapse rate after stopping drug treatment and speed up the negative conversion of HBV DNA, the treatment effect is satisfactory ; The combination of two drugs acting on different targets and mechanisms, respectively, mutual promotion can improve the curative effect and reduce the incidence of lamivudine resistance.